Supernus Pharmaceuticals 8-K Report: Key Insights from December 19, 2024 Filing
Here are the key insights extracted from the provided section of the financial report for Supernus Pharmaceuticals, Inc.:
- Filing Type: The document is an 8-K filing, which is typically used to report unscheduled material events or corporate changes.
- Company Information:
- Name: Supernus Pharmaceuticals, Inc.
- State of Incorporation: Delaware (DE)
- CIK Number: 0001356576
- Stock Ticker: SUPN
- Exchange: NASDAQ
- Reporting Date: The period covered by this report is a single day, December 19, 2024.
- Business Address:
- Location: 9715 Key West Ave, Rockville, MD 20850
- Phone: 301-838-2500
- Share Information: The company has common stock with a par value of $0.001 per share.
- Filing Context: The XML structure indicates that this filing is part of a structured financial reporting system (XBRL), which is designed for easier data analysis and reporting.
- Schema Reference: The filing references an XSD schema named "supn-20241219.xsd," which outlines the structure of the data included in this filing.
This information is critical for stakeholders, analysts, and investors who may be tracking the company's financial health and regulatory compliance.